Results presented in a late-breaking clinical trial presentation at the American Heart Association’s Scientific Sessions 2020 reported that large randomised trial demonstrated that a simple polypill (containing cholesterol and blood pressure control medication) could significantly reduce cardiovascular risk.
In the International Polycap Study (TIPS)-3, 5700 participants in 9 countries were given either the polypill, aspirin, the polypill plus aspirin or Vitamin D and monitored for five years for major cardiovascular events.
The polypill contained atenolol 100mg, ramipril 10mg, hydrochlorothiazide 25 mg, and simvastatin 40 mg.
The combination of polypill and aspirin reduced cardiovascular events by 31%, whilst aspirin alone had a 14% reduction and 21% with polypill alone.
Salim Yusuf, MD, BS, D Phil, co-author of the study said, “Aspirin should be prescribed with a polypill in primary prevention for patients at intermediate risk of heart disease. Our study results provide important data regarding the role of the polypill in preventing the development of heart disease.”
Source: News-Medical.Net
